1. An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2. Issue 3 (13th November 2021) Authors: Walker, Lauren E.; FitzGerald, Richard; Saunders, Geoffrey; Lyon, Rebecca; Fisher, Michael; Martin, Karen; Eberhart, Izabela; Woods, Christie; Ewings, Sean; Hale, Colin; Rajoli, Rajith K. R.; Else, Laura; Dilly‐Penchala, Sujan; Amara, Alieu; Lalloo, David G.; Jacobs, Michael; Pertinez, Henry; Hat... Journal: Clinical pharmacology & therapeutics Issue: Volume 111:Issue 3(2022) Page Start: 585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. (27th August 2021) Authors: Khoo, Saye H; Fitzgerald, Richard; Fletcher, Thomas; Ewings, Sean; Jaki, Thomas; Lyon, Rebecca; Downs, Nichola; Walker, Lauren; Tansley-Hancock, Olana; Greenhalf, William; Woods, Christie; Reynolds, Helen; Marwood, Ellice; Mozgunov, Pavel; Adams, Emily; Bullock, Katie; Holman, Wayne; Bula, Marcin... Journal: Journal of antimicrobial chemotherapy Issue: Volume 76:Number 12(2021) Page Start: 3286 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗